Journal of Clinical Lipidology Impact Factor Increases to 6.9

The National Lipid Association (NLA) is pleased to announce that the Journal of Clinical Lipidology (JCL), the Association’s official peer-reviewed journal, has achieved an Impact Factor of 6.9 in the 2025 Journal Citation Reports™ (Clarivate), representing a substantial increase from 4.9 in 2024.

This notable advancement reflects the journal’s growing influence within the fields of lipidology, preventive cardiology, and ASCVD risk reduction, as well as the exceptional quality of research, clinical guidance, and educational content published in its pages.

The NLA is honored and delighted to celebrate the remarkable growth of JCL’s Impact Factor to 6.9, an outstanding two points up from the previous year,” said Dinesh Kalra, MD, FNLA, President of the National Lipid Association. “Scientific innovation, discovery, publication, and dissemination are central to the NLA's mission. Through JCL, the NLA advances discovery and fosters education by publishing emerging science, research innovations, scientific statements, and important clinical papers. Achieving this milestone is a testament to the quality, rigor, and value of the work being published in the JCL and reflects the high quality of our authors, reviewers, and editorial board. Many NLA members are leading scientists and investigators whose dedication and scholarship have played a vital role in the journal's success. We are proud to recognize their contributions and grateful for the exceptional leadership of the Editorial Board and staff. Their vision and dedication have helped advance NLA's mission and establish JCL as a premier publication in prevention, lipidology, and cardiometabolic medicine.”

Since its inception, the Journal of Clinical Lipidology has served as a trusted source for original research, clinical reviews, NLA scientific publications, and practice guidance that support clinicians and scientists in improving patient outcomes. The journal’s rising Impact Factor highlights the growing recognition and citation of its published work across the global scientific and medical communities.

“Dr. Duell and I are very pleased with the progress of the journal, which is a testament to the high quality of the papers we have received from around the world,” said Kevin C. Maki, PhD, CLS, MNLA, Co-Editor-in-Chief of the Journal of Clinical Lipidology. “We are grateful to the editors, reviewers, and the people at the NLA and Elsevier who have supported the continued development of JCL into a top publication in the field.”

As the field continues to evolve with new therapies, technologies, and approaches to cardiovascular prevention, the NLA is excited for the opportunities provided by the Journal of Clinical Lipidology and remains committed to publishing high-quality, clinically relevant research that informs practice and improves patient care worldwide.